Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. Mascarella MA, Olonisakin TF, Rumde P, Vendra V, et al. Clin Cancer Res 2023 Jan 3:CCR-22-1768. doi: 10.1158/1078-0432.CCR-22-1768.

Read + Share

Amedeo Smart

Independent Medical Education

Mascarella MA, Olonisakin TF, Rumde P, Vendra V, et al. Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit. Clin Cancer Res 2023 Jan 3:CCR-22-1768. doi: 10.1158/1078-0432.CCR-22-1768.
PMID: 36595540